Moleculin Biotech (MBRX) Research & Development (2016 - 2026)
Moleculin Biotech's Research & Development came in at $5.45 million for Q2 2026, up 51.4% from $3.6 million a year earlier.
Powered by 
Analysis
Moleculin Biotech (MBRX) Research & Development (2016 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Moleculin Biotech reported Research & Development of $17.91 million, up 9.0% year-over-year; for FY2025, it came in at $15.89 million, down 10.4% from FY2024.
- Research & Development carries a five-year compound annual growth rate of 4.5% (FY2020 to FY2025).
- Going back by year, Research & Development was $17.73 million in FY2024 (-9.0%), $19.49 million in FY2023 (+2.7%), $18.97 million in FY2022 (+31.6%) and $14.42 million in FY2021 (+13.0%).
- The Q2 2026 figure represents the highest quarterly Research & Development since Q4 2023.
- Year-over-year, Research & Development increased in three of the last seven quarters, with growth averaging 4.1%.
- The fastest year-over-year change in Research & Development over five years came in Q4 2021 (growth of 78.0%), and the weakest in Q3 2023 (a decline of 45.0%).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | -4.05 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 993.80 Mn |
| 10 | Moleculin Biotech | 3.24 Mn | 3.24 Mn | - | 5.45 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.45 Mn |
| Dec 31, 2025 | 5.12 Mn |
| Sep 30, 2025 | 3.74 Mn |
| Jun 30, 2025 | 3.60 Mn |
| Mar 31, 2025 | 3.44 Mn |
| Dec 31, 2024 | 4.46 Mn |
| Sep 30, 2024 | 4.93 Mn |
| Jun 30, 2024 | 4.09 Mn |
| Mar 31, 2024 | 4.25 Mn |
| Dec 31, 2023 | 6.63 Mn |
| Sep 30, 2023 | 3.28 Mn |
| Jun 30, 2023 | 3.89 Mn |
| Mar 31, 2023 | 5.69 Mn |
| Dec 31, 2022 | 4.18 Mn |
| Sep 30, 2022 | 5.97 Mn |
| Jun 30, 2022 | 4.20 Mn |
| Mar 31, 2022 | 4.62 Mn |
| Dec 31, 2021 | 3.18 Mn |
| Sep 30, 2021 | 4.10 Mn |
| Jun 30, 2021 | 3.04 Mn |
API Access
Moleculin Biotech Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=MBRX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "MBRX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=MBRX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();